ArticleResearch square2025
Tumoroid model recreates clinically relevant phenotypes of high grade serous ovarian cancer (HGSC) cells, carcinoma associated fibroblasts, and macrophages.
Article in Research square, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
- Updated by
Authors and funding
9 authors.
Funding
Abstract
Ovarian cancer, the gynecological malignancy with the lowest survival rate, is significantly influenced by the tumor microenvironment. The mesenchymal subtype of high-grade serous carcinoma (HGSC) shows poor outcomes due to high stromal and low immune response. Single-cell RNA sequencing (scRNA-seq) of HGSC metastatic ascites has identified carcinoma-associated fibroblasts (CAFs), macrophages, and carcinoma-associated mesenchymal stem cells (CA-MSCs) as crucial drivers of immune exclusion, chemotherapy resistance, metastasis, and stem-like cell propagation. To explore this complex signaling, we developed heterogeneous tri-component tumoroids, incorporating HGSC cells (OVCAR3, OVCAR4, OVCAR8), primary MSCs, and U937-derived M2-like macrophages (M2-AAM) in defined ratios, each labeled with a fluorescent protein for distinct analysis. Upon a 48-hour treatment with carboplatin and/or paclitaxel, HGSC cells in tri-component tumoroids exhibited higher chemoresistance than HGSC-only spheroids. Flow cytometry revealed significant increases in cancer stem-like cell (CSC) markers CD44 and CD90 in the tri-component tumoroids. Conditioned medium from the tri-component tumoroids significantly enhanced HGSC cell migration compared to spheroids. Invasion assays further demonstrated that tri-component tumoroids penetrated monolayer of mCherry-labeled LP-9 mesothelial cells more effectively than spheroids. Additionally, scRNA-seq of tri-component tumoroids identified a unique cancer cell cluster enriched in epithelial-mesenchymal transition (EMT) and matrisome signatures, featuring a 14-gene signature linked to poor survival. MSCs in these tri-component tumoroids displayed a myofibroblastic-CAF signature, while macrophages indicated an ECM-associated and immunosuppressive phenotype. In conclusion, our 3D heterogenous tri-component tumoroids replicate key HGSC phenotypes, such as chemoresistance, CSC enrichment, migration, invasion, and EMT. This platform is invaluable for studying HGSC microenvironment interactions and preclinical testing of targeted therapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.